IQVIA
About: Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Employees: 89,000
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 12 (+2) [Q1 2025]
1.74% more ownership
Funds ownership: 84.76% [Q4 2024] → 86.5% (+1.74%) [Q1 2025]
3% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 104
3% less repeat investments, than reductions
Existing positions increased: 362 | Existing positions reduced: 375
2% less funds holding
Funds holding: 991 [Q4 2024] → 973 (-18) [Q1 2025]
11% less capital invested
Capital invested by funds: $30.2B [Q4 2024] → $26.8B (-$3.42B) [Q1 2025]
35% less call options, than puts
Call options by funds: $124M | Put options by funds: $191M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$160
2%
downside
Avg. target
$174
7%
upside
High target
$190
17%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
Evercore ISI Group Elizabeth Anderson | 11%upside $180 | Outperform Maintained | 9 Jul 2025 |
JP Morgan Anne Samuel | 9%upside $177 | Overweight Maintained | 19 May 2025 |
Mizuho Ann Hynes | 17%upside $190 | Outperform Maintained | 15 May 2025 |
Baird Eric Coldwell | 1%downside $161 | Neutral Maintained | 7 May 2025 |
UBS Dan Leonard | 14%upside $185 | Buy Maintained | 7 May 2025 |
Financial journalist opinion
Based on 4 articles about IQV published over the past 30 days
Positive
Zacks Investment Research
15 hours ago
Why IQVIA Holdings (IQV) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
Business Wire
1 week ago
IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanyi.
Neutral
Investors Business Daily
2 weeks ago
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will it work?
Neutral
Business Wire
3 weeks ago
IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the “Best Mobile App for Patient Engagement” in the ninth-annual MedTech Breakthrough Awards program. IQVIA's breakthrough Health Research Space platform allows direct-to-patient data collection and engagement with patient-facing mobile apps that.
Neutral
Business Wire
1 month ago
IQVIA Launches New AI Agents for Life Sciences and Healthcare
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA's new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI and deep domain expertise are transformi.
Neutral
Benzinga
1 month ago
IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?
IQVIA (IQV) is currently in Phase 18 of its 18-Phase Adhishthana Cycle. On the surface, the stock might appear poised for a new move, but when analyzed through a multi-timeframe lens using the Adhishthana Principles, the picture is more complex.
Neutral
Business Wire
1 month ago
IQVIA Announces Pricing of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2032 (the “Notes”). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other gen.
Neutral
Business Wire
1 month ago
IQVIA Announces Offering of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the “Notes”). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate.
Neutral
PRNewsWire
1 month ago
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas , May 27, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF. "We are pleased to have dosed the first patient in our RENEW Phase 2 trial of LTI-03 following initiation of the trial.
Neutral
Business Wire
1 month ago
IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development.
Charts implemented using Lightweight Charts™